Search Tufts Medicine

This is a research study being conducted in patients who tested positive for COVID-19 in the past 10 days and are admitted to the hospital. The study is being conducted to assess the safety of an experimental drug called Reparixin. This is provided as tablets along with standard treatment to limit progression of Covid-19 disease. This is a randomized, (which means just like tossing a coin, you will be randomly assigned to receive the study drug or the standard treatment) double-blind trial (which means neither you nor the study team will know which group you are assigned to).

This study is being conducted in healthy children from age 6 months to age 12 years. The study is looking at how well the Moderna mRNA vaccine works when given to healthy children for the prevention of COVID-19.

This is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial evaluating antiviral and other therapeutics for use in the treatment of Post-Acute Sequelae of COVID-19 (PASC). The hypothesis is that persistent viral infection and/or overactive/chronic immune response are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.

The purpose of the study is to learn about the problems that some individuals who recover from a COVID-19 infection continue to have months after they recover from the initial phase of the infection. We will be performing specific type of imaging called x-ray velocimetry. This allows us to understand regional lung ventilation. We will be examining if the measures of regional lung ventilation are more abnormal in participants who have previously had COVID-19 compared to those who have not previously acquired this infection.